On 29 August 2016, orphan designation (EU/3/16/1721) was granted by the European Commission to Araim Pharma Europe Ltd, United Kingdom, for L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (also known as ARA 290) for the prevention of graft loss in pancreatic islet transplantation.
This medicine is now known as cibinetide.
The sponsorship was transferred to Araim Pharmaceuticals Europe Limited, Ireland, in April 2019.
|Disease / condition||
Prevention of graft loss in pancreatic islet transplantation
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;